drugset
drugset / Trial / NCT02481297

Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

NCT02481297 ↗

Phase 2 Completed 7 enrolled M.D. Anderson Cancer Center Bristol-Myers Squibb · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if lirilumab in combination with rituximab can help to control either CLL or Small lymphocytic lymphoma (SLL). The safety of the drug combination will also be studied.

Timeline

Start
2015-06-23
Primary completion
2019-08-15
Completion
2019-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Lirilumab Monoclonal antibody 3 mg/kg Intravenous
Subject Rituximab Monoclonal antibody 375 mg/m2 —

Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma